These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
148 related articles for article (PubMed ID: 26666161)
1. [The trend of new drug development for the treatment of diabetes mellitus]. Kaku K Nihon Rinsho; 2015 Dec; 73(12):2108-14. PubMed ID: 26666161 [TBL] [Abstract][Full Text] [Related]
3. Liraglutide (Victoza) for type 2 diabetes. Med Lett Drugs Ther; 2010 Apr; 52(1335):25-7. PubMed ID: 20360660 [TBL] [Abstract][Full Text] [Related]
4. Are we waiting too long for the cardiovascular outcome trials with the glucagon-like peptide-1 receptor agonists? Doggrell SA Expert Opin Drug Saf; 2015 Jun; 14(6):801-5. PubMed ID: 25891299 [TBL] [Abstract][Full Text] [Related]
5. The cardiovascular effects of glucagon-like peptide-1 receptor agonists: a trial sequential analysis of randomized controlled trials. Wu S; Sun F; Zhang Y; Yang Z; Hong T; Chen Y; Zhan S J Clin Pharm Ther; 2014 Feb; 39(1):7-13. PubMed ID: 24127768 [TBL] [Abstract][Full Text] [Related]
6. Medicinal chemistry of glucagon-like peptide receptor agonists. Jones LH; Price DA Prog Med Chem; 2013; 52():45-96. PubMed ID: 23384666 [No Abstract] [Full Text] [Related]
7. Cardiovascular effects of GLP-1 and GLP-1-based therapies: implications for the cardiovascular continuum in diabetes? Burgmaier M; Heinrich C; Marx N Diabet Med; 2013 Mar; 30(3):289-99. PubMed ID: 22804451 [TBL] [Abstract][Full Text] [Related]
8. [Extrapancreatic effects of GLP-1 receptor agonists: an open window towards new treatment goals in type 2 diabetes]. Salvador J; Andrada P Med Clin (Barc); 2014 Sep; 143 Suppl 2():28-34. PubMed ID: 25437463 [TBL] [Abstract][Full Text] [Related]
10. Strategies for the development of new PPAR agonists in diabetes. Cavender MA; Nicholls SJ; Lincoff AM Eur J Cardiovasc Prev Rehabil; 2010 May; 17 Suppl 1():S32-7. PubMed ID: 20489419 [TBL] [Abstract][Full Text] [Related]
16. Developing new drugs for diabetes and cardiometabolic disorders: a changing paradigm. Krentz AJ; Morrow L; Hompesch M Drugs; 2012 Sep; 72(13):1709-11. PubMed ID: 22931519 [No Abstract] [Full Text] [Related]
17. Bringing liraglutide to market: a CER case study. Oderda G; Sifford-Wilson SM J Manag Care Pharm; 2012 Jun; 18(5 Supp A):S12-8. PubMed ID: 22663295 [TBL] [Abstract][Full Text] [Related]
18. [Current aspects of the mechanism of action of calcium antagonists in patients with diabetes mellitus]. Kostiuk OP; Zubkova ST Fiziol Zh (1978); 1992; 38(3):106-11. PubMed ID: 1499754 [TBL] [Abstract][Full Text] [Related]
19. Effects of glucagon-like peptide-1 receptor agonists on cardiovascular risk: a meta-analysis of randomized clinical trials. Monami M; Dicembrini I; Nardini C; Fiordelli I; Mannucci E Diabetes Obes Metab; 2014 Jan; 16(1):38-47. PubMed ID: 23829656 [TBL] [Abstract][Full Text] [Related]